Navigation Links
FASgen Announces a New Discovery in Obesity Research
Date:12/21/2007

BALTIMORE, Dec. 21 /PRNewswire/ -- FASgen is pleased to report the publication of important new research results in the obesity field using FAS89B, one of the Company's proprietary compounds. FASgen is a leader in the field of research into selective inhibition of fatty acid synthase (FASi), and has conducted extensive research in the area of metabolic disease disorders, specifically for the treatment of obesity and fatty liver disease. The Company has a long-standing cooperation with The Johns Hopkins University, and that joint research has produced the new discoveries in the regulation of weight loss by the stimulation of carnitinepalmitoyl-transferase-1 (CPT-1). FAS89B was characterized in vitro as a selective inhibitor of brain CPT-1 and produced in vivo results in mice of decreased feeding for three days and persistent weight loss of six days, with no evidence of conditioned taste aversion. See, "Pharmacological Stimulation of Brain Carnitine-Transerase-1 Decreases Food Intake and Body Weight," Ronnett, et al, Am J Physiol Regul Integr Physiol (December 8, 2007). This new discovery adds another tool for FASgen to use, in addition to FASi and GPATi compounds already in research, in its ongoing program of research into the field of treatment for obesity and fatty liver disease.

About FASgen, Inc.: FASgen, Inc. is a drug development company founded in 2000 by four distinguished Johns Hopkins researchers to create new therapeutic products based on the selective inhibition of fatty acid biosynthesis. The Company has the exclusive license from Johns Hopkins to more than 15 years of research in the field, which research continues under a sponsored research agreement with the University.

The Company has designed and synthesized many compounds that selectively inhibit fatty acid biosynthesis. One group of these compounds holds great promise for new highly specific therapeutics for cancer; additional compounds have the potential of specific therapeutics for obesity and related metabolic disorders; and, an additional group of compounds have the potential of specific therapeutics for TB, including multiple drug resistant TB (MDR-TB) and latent TB infections that affect one third of the world's population. For more information, visit FASgen's website at http://www.fasgen.com.


'/>"/>
SOURCE FASgen, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. FASgen Announces Significant Milestone in Its Cancer Drug Development Program
2. FASgen Announces New Discovery for Treatment of Stroke
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
8. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
9. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
10. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
11. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... , Feb. 4, 2016 Worldwide ... achieve significant growth as next generation systems provide ... use radiology for cancer surgery. New systems pinpoint ... overdosing that has been such a problem previously, ... delivered. Radiosurgery robots take cancer surgery far beyond ...
(Date:2/4/2016)... 4, 2016 Summary Breast cancer, a ... the most common cancer in women worldwide, accounting for ... prevalent. The number of women diagnosed with breast cancer ... number of deaths has declined due to earlier diagnosis ... been revolutionized in the past four decades, especially with ...
(Date:2/4/2016)... DIEGO, Feb. 4, 2016  Aethlon Medical, Inc. ... affinity biofiltration devices to treat life-threatening diseases, today ... 2016 ended December 31, 2015. ... objectives set forth in our last quarterly call, ... reinforce our long-term objective to establish the Aethlon ...
Breaking Medicine Technology:
(Date:2/6/2016)... ... February 06, 2016 , ... Shark Finds and ... launch of a new DRTV campaign with Belly Bands. , Having a dog is ... sprays to puppy pads and find nothing works, get Belly Bands, the easiest ...
(Date:2/5/2016)... Bethpage, NY (PRWEB) , ... February 05, 2016 , ... ... florist-quality long-stem roses in a variety of colors, assortments and packaging. This staple for ... at any King Kullen location. , For Valentine’s Day, not only are long-stem ...
(Date:2/5/2016)... ... February 05, 2016 , ... Successful recruitment and retention efforts, ... scientific initiatives have all marked the last 12 months at Roswell Park Cancer ... the nation’s oldest cancer center, Candace S. Johnson, PhD, outlined the many accomplishments ...
(Date:2/5/2016)... ... 05, 2016 , ... Francisco Canales, MD and Heather Furnas, ... Valley office. The technique utilizes the body’s own healing abilities to quickly rejuvenate ... are part of only a select few cosmetic surgeons bringing this procedure to ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... After years ... General Hospital Burn Unit, plastic and cosmetic surgeon Dr. Wayne Carman transitioned to chief ... Hospital. He successfully completed his first three-year term as chief and began a second ...
Breaking Medicine News(10 mins):